New trends in antiretroviral therapy for HIV infection

European Journal of Internal Medicine

Volumn 11, Issue 6, 2000, Pages 301-308

  Joly, Véronique ^a   Yeni, Patrick ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Antiretroviral drugs; HIV

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYTOCHROME P450 3A; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; FATIGUE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNOTHERAPY; IN VITRO STUDY; INDIVIDUALIZATION; INSULIN RESISTANCE; LACTIC ACIDEMIA; LIPOATROPHY; LYMPHOCYTE COUNT; NAUSEA; PATIENT COMPLIANCE; RASH; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE;

EID: 0033674168     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(00)00112-6     Document Type: Review

References (60)

1. Factors predictive of durable HIV suppression in a randomized double blind trial with nevirapine, zidovudine and lamivudine in treatment-naive patients with advanced AIDS
2. Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CNA 3005)
3. The Atlantic study: A randomized, open-label trial comparing two protease inhibitor-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data
4. Longer time to treatment failure and durability of response with efavirenz+ZDV+3TC: First analysis of full 1266 patients cohort from study 006
5. Sustained plasma viral burden reductions and CD4 increases in HIV-1 infected patients with rescriptor+retrovir+epivir
6. First comparative study of saquinavir soft gel capsules vs. indinavir as part of a triple therapy regimen (CHEESE)
7. Multiple-dose pharmacokinetics and tolerability of indinavir and ritonavir combinations in a once-daily regimen in healthy volunteers (Merck 089)
8. Dose-finding study of a once daily indinavir/ritonavir regimen in healthy volunteers
9. Saquinavir systemic exposure and safety of once daily administration of Fortovase® soft gel capsule in combination with low-dose ritonavir
10. A randomized trial of three maintenance regimens given after 3 months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated patients, Trilege Study Team
11. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam duration of antiretroviral medication (ADAM) study
12. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group 343 Team
13. Risks and benefits of replacing protease inhibitors by nevirapine in patients with long-term successful triple combinations
14. Protease inhibitor class-sparing maintenance therapy with abacavir+lamivudine+zidovudine in patients with long-term suppression of HIV-1 RNA
15. A phase I/II randomized, controlled study of FTC versus 3TC in HIV infected patients
16. A pilot study of FTC+ddI+efavirenz in treatment naive HIV-infected adults: A potent and convenient once-a-day HAART (ANRS 091 trial)
17. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
18. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
19. Pharmacodynamics of indinavir in protease-naive HIV-infected patients receiving ZDV and 3TC
20. ABT-378/ritonavir suppresses HIV RNA to <400 copies/ml in 84% of PI-experienced patients at 48 weeks
21. Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic and pharmacologic variables
22. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
23. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
24. Phenotypic resistance testing significantly improved response to therapy: A randomized trial (VIRA 3001)
25. The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine Prometheus Study Group
26. Combination of zidovudine and stavudine therapy versus other nucleosides: Report of two randomized trials (ACTG 290 and 298)
27. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
28. Selection of HIV-1 variants with wide cross-resistance to reverse transcriptase inhibitors during low-level escape to first line dual nucleoside therapy
29. Genotypic and phenotypic correlates of response to abacavir
30. Randomized trial of abacavir and nelfinavir in combination with efavirenz and adefovir dipivoxil as salvage therapy in patients with virologic failure receiving indinavir
31. The efficacy of ritonavir/saquinavir antiretroviral therapy in patients who failed nelfinavir: A multicenter clinical cohort study
32. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
33. Differences in protease inhibitor phenotypic susceptibility after failure of the first PI-containing regimen
34. Durability of abacavir/amprenavir/efavirenz combination salvage therapy - Preliminary 48-week response (CNA 2007)
35. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations
36. Pharmacokinetic (PK) evaluation of saquinavir soft gel capsules/ritonavir or SQV/nelfinavir in combination with delavirdine and/or adefovir dipivoxil-ACTG 359
37. Novel four-drug salvage treatment regimen after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
38. Baseline resistance and virological response to Mega-HAART salvage therapies
39. Virologic and immunologic evaluation of structured treatment interruptions in patients experiencing long-term virologic failure
40. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
41. Visceral abdominal-fat accumulation associated with use of indinavir
42. Buffalo hump in men with HIV-1 infection
43. A syndrome of peripheral wasting lipodystrophy in patients receiving long-term nucleoside analogue therapy
44. Noninvasive morphological analysis of carotid and femoral arteries in protease-inhibitor-treated HIV-infected individuals
45. A pilot study of carotid intima media thickness in HIV-infected women treated with protease inhibitors
46. Detection of myocardial ischemia in protease inhibitor-treated HIV-infected patients with hyperlipemia
47. Do protease inhibitors increase the risk for coronary heart disease among HIV-positive patients? Additional follow-Up
48. Myocardial infarction incidence in clinical trials of 4 protease inhibitors
49. Osteopenia in a randomized, multicenter study of protease inhibitor substitution in patients with the lipodystrophy syndrome and well-controlled HIV viremia
50. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
51. Randomized trial of continued indinavir (IDV)/ZDV/3TC vs. switch to IDV/ddI/d4T or IDV/ddI/d4T+hydroxyurea in patients with viral suppression
52. Effect of T-cell activation under HAART on the long-lived reservoir of HIV-infected quiescent CD4+T cells: Implications for treatment, homeostasis, and pathogenesis in HIV infection
53. Positive effects of combined antiretroviral therapy on CD4+T cell homeostasis and function in advanced HIV disease
54. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment
55. Control of HIV despite the discontinuation of antiretroviral therapy
56. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
57. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
58. Dynamics of viral load rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
59. Increase in breadth and frequency of CTL responses after structured treatment interruptions in individuals treated with HAART during acute HIV-1 infection
60. SITT: A prospective trial of strategic treatment interruptions